ライフサイエンスコーパス: mycosis

1 gal infection and 13 isolates from cutaneous mycosis).

2 a potential source of a vaccine against this mycosis.

3 ctive cases of the disseminated form of this mycosis.

4 as a promising model to study this important mycosis.

5 lished model of an allergic bronchopulmonary mycosis.

6 .e., a model of an allergic bronchopulmonary mycosis.

7 pressed genes (DEGs) was highest during late mycosis (72 h post-infection).

8 Allergic bronchopulmonary mycosis (ABPM) is a hypersensitivity lung disease in whi

9 characteristics of allergic bronchopulmonary mycosis (ABPM).

10 ost common form of allergic bronchopulmonary mycosis (ABPM); other fungi, including Candida, Penicill

11 Currently, drugs used clinically for deep mycosis act by binding ergosterol or disrupting its bios

12 Epidemiological data on this type of mycosis are scant.

13 Fusarium Research Center) cultures of novel mycosis-associated fusaria, along with associated, corre

14 All of the mycosis-associated isolates were restricted to FSSC clad

15 Histoplasmosis, a systemic mycosis caused by the fungus Histoplasma capsulatum, pri

16 nicillium marneffei is an emerging dimorphic mycosis endemic in Southeast Asia, and a leading cause o

17 /6 mice develop an allergic bronchopulmonary mycosis following intratracheal inoculation of Cryptococ

18 all of which were from the 44 patients with mycosis fungoides (10/44 patients; 23%).

19 n 18 patients (25%), including 12 of 57 with mycosis fungoides (21%) and six of 16 with Sezary syndro

20 as found to be more prevalent in tumor stage mycosis fungoides (47%) than early stage disease (20%) a

21 tificates for two such cancers, melanoma and mycosis fungoides (a cutaneous lymphoma), using routinel

22 Malignant melanoma and mycosis fungoides (cutaneous T cell lymphoma) are rare m

23 s suggest that patients with folliculotropic mycosis fungoides (FMF) have a worse prognosis than pati

24 mantle cell lymphoma (MCL) (8% [n = 7]), and mycosis fungoides (MF) (9% [n = 8]).

25 (CTCL) comprising 10 cases with early-stage mycosis fungoides (MF) and 10 cases with late-stage MF o

26 SHV/HHV-8 is involved in the pathogenesis of mycosis fungoides (MF) and related disorders, we used a

27 Transformed mycosis fungoides (MF) and Sezary syndrome (SS) are curr

28 Mycosis fungoides (MF) and Sezary syndrome (SS) are the

29 ective retinoid that can induce apoptosis of mycosis fungoides (MF) and Sezary syndrome (SS) cells.

30 umor, node, metastases (TNM) system used for mycosis fungoides (MF) and Sezary syndrome (SS) is not a

31 CD30 expression of malignant lymphocytes in mycosis fungoides (MF) and Sezary syndrome (SS) is quite

32 ogy and diagnostic techniques as pertains to mycosis fungoides (MF) and Sezary syndrome (SS) since th

33 ic treatment options exist for patients with mycosis fungoides (MF) and Sezary syndrome (SS), but no

34 MTAP in cutaneous T-cell lymphoma subgroups, mycosis fungoides (MF) and Sezary syndrome (SS), is unkn

35 Mycosis fungoides (MF) and Sezary syndrome (SS), the maj

36 treatment of CTCL, with specific emphasis on mycosis fungoides (MF) and Sezary syndrome (SS).

37 months) in heavily pretreated patients with mycosis fungoides (MF) and Sezary syndrome (SS).

38 xyadenosine (2-CdA) therapy in patients with mycosis fungoides (MF) and the Sezary syndrome (SS).

39 Sezary syndrome (SS) and tumor-stage mycosis fungoides (MF) are generally incurable with curr

40 Neoplastic T cells in mycosis fungoides (MF) are resistant to apoptotic agents

41 Mycosis fungoides (MF) is a cutaneous T-cell lymphoma ch

42 Mycosis fungoides (MF) is a low-grade lymphoma of cluste

43 Large cell transformation (LCT) in mycosis fungoides (MF) is generally associated with an a

44 Mycosis fungoides (MF) is the most common form of cutane

45 Mycosis fungoides (MF) is the most common primary cutane

46 Mycosis fungoides (MF) is the most common primary cutane

47 Mycosis fungoides (MF) is the most common subtype of cut

48 Mycosis fungoides (MF) is the most frequent form of cuta

49 Mycosis fungoides (MF) is the most frequent manifestatio

50 Although mycosis fungoides (MF) is typically an indolent disease,

51 Although mycosis fungoides (MF) may arise through persistent anti

52 e cell lymphoma (ALCL) of 2 patients and the mycosis fungoides (MF) of 2 other patients.

53 hrough stage IIA) cutaneous T-cell lymphoma, mycosis fungoides (MF) type, resulted in clinical respon

54 Because patients with mycosis fungoides (MF) usually do not have such antibodi

55 ND1/BCL1 expression in 18 of 30 SS, 10 of 23 mycosis fungoides (MF), and three of 10 primary cutaneou

56 patients with the cutaneous T-cell lymphoma, mycosis fungoides (MF), are seronegative for human T-cel

57 catter T (T(HS)) cells were CD4(+) in CD4(+) mycosis fungoides (MF), CD8(+) in CD8(+) MF, and contain

58 The histopathologic diagnosis of mycosis fungoides (MF), even when clinical manifestation

59 mphoma (CTCL), including Sezary syndrome and mycosis fungoides (MF), is poor.

60 sis of the cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF), is unclear.

61 (CTCL) may present with eczematous lesions, mycosis fungoides (MF), or as exfoliative erythroderma w

62 patients with a diagnosis of CTCL, including mycosis fungoides (MF), Sezary syndrome (SS), or CTCL no

63 The pathogenesis of mycosis fungoides (MF), the most common cutaneous T-cell

64 f inflammatory cytokines in 12 patients with mycosis fungoides (MF), the most common variant of CTCL.

65 a worse prognosis than patients with classic mycosis fungoides (MF).

66 A skin biopsy confirmed mycosis fungoides (MF).

67 explored this strategy in a second disease: mycosis fungoides (MF).

68 proliferative disorders (CD30CLPD) and early mycosis fungoides (MF).

69 SS) and primarily cutaneous variants such as mycosis fungoides (MF).

70 od lymphocyte cultures from 19 patients with mycosis fungoides (MF)/Sezary syndrome (SS) stimulated w

71 Advanced-stage mycosis fungoides (MF; stage IIB to IV) and Sezary syndr

72 .1% in Sezary syndrome (n = 17) and 28.6% in mycosis fungoides (n = 21).

73 ients with Sezary syndrome (SS), transformed mycosis fungoides (T-MF), and cutaneous anaplastic large

74 ients with treatment refractory CD4(+) CTCL (mycosis fungoides [MF], n = 38; Sezary syndrome [SS], n

75 pendent prognostic variable in patients with mycosis fungoides after correcting for age, skin, and ly

76 the 54 samples (24%), 12 from patients with mycosis fungoides and 1 from a patient with Sezary syndr

77 have analyzed 51 samples from patients with mycosis fungoides and 15 with Sezary syndrome using meth

78 uding losses on 9p21 in 16% of patients with mycosis fungoides and 46% with Sezary syndrome.

79 lic loss was present in 45% of patients with mycosis fungoides and 67% with Sezary syndrome.

80 tested SS patients but not in patients with mycosis fungoides and atopic dermatitis or HD.

81 Mycosis fungoides and its leukemic variant, Sezary syndr

82 Mycosis fungoides and Sezary syndrome (MF/SS) are rare i

83 common in both early and advanced stages of mycosis fungoides and Sezary syndrome and that these gen

84 Mycosis fungoides and Sezary syndrome are the most commo

85 Mycosis fungoides and Sezary syndrome are two major form

86 Although the aetiologies of mycosis fungoides and Sezary syndrome are unknown, impor

87 Mycosis fungoides and Sezary syndrome comprise the major

88 approximately 30% of patients with advanced mycosis fungoides and Sezary syndrome cutaneous T-cell l

89 aneous T-cell lymphoma (CTCL), including the mycosis fungoides and Sezary syndrome forms of the disea

90 ined lesional skin biopsy specimens from 113 mycosis fungoides and Sezary Syndrome patients for activ

91 lly reverse or suppress the abnormalities of mycosis fungoides and Sezary syndrome to the point at wh

92 ous T-cell lymphoma (CTCL), particularly the mycosis fungoides and Sezary syndrome variants, has been

93 276 patients with cutaneous T cell lymphoma (mycosis fungoides and Sezary syndrome) using 2,4-dinitro

94 oproliferative processes, mainly composed of mycosis fungoides and Sezary syndrome, the aggressive fo

95 Discoveries regarding the pathophysiology of mycosis fungoides and Sezary syndrome, the two most comm

96 ous T-cell lymphoma with special emphasis on mycosis fungoides and Sezary syndrome.

97 candidate tumor suppressor genes involved in mycosis fungoides and Sezary syndrome.

98 h cutaneous T-cell lymphoma (CTCL) including mycosis fungoides and Sezary syndrome.

99 ctor receptor TNFR2, in 18% of patients with mycosis fungoides and Sezary syndrome.

100 subtypes of the disease, the most common are mycosis fungoides and Sezary syndrome.

101 logy of cutaneous T-cell lymphoma, including mycosis fungoides and Sezary syndrome.

102 Mycosis fungoides and the Sezary syndrome represent a he

103 g, prognosis, and treatment of patients with mycosis fungoides and the Sezary syndrome.

104 Sezary syndrome and mycosis fungoides are related chronic lymphoproliferativ

105 The ISCL/EORTC recommends revisions to the Mycosis Fungoides Cooperative Group classification and s

106 aviolet B-related step in the progression of mycosis fungoides from plaque to tumor-stage disease.

107 Mycosis fungoides is a cutaneous malignancy usually foun

108 0.02%, gel in the treatment of patients with mycosis fungoides is effective and safe.

109 osity was found in over 10% of patients with mycosis fungoides on 9p, 10q, 1p, and 17p and was presen

110 e enrolled adult patients with CD30-positive mycosis fungoides or primary cutaneous anaplastic large-

111 s had anaplastic large-cell lymphoma, 15 had mycosis fungoides or Sezary syndrome (14 with large-cell

112 id) in persistent, progressive, or recurrent mycosis fungoides or Sezary syndrome (MF/SS) cutaneous t

113 ve therefore studied 76 patients with either mycosis fungoides or Sezary syndrome for abnormalities o

114 uppression, such that patients with advanced mycosis fungoides or Sezary syndrome have been compared

115 utaneous T-cell lymphoma (CTCL), or subtypes mycosis fungoides or Sezary syndrome, who had received n

116 haracteristically slow, we hypothesized that mycosis fungoides originates from an accumulation of lym

117 bility, a study on specimens of relatives of mycosis fungoides patients (MFR) was begun.

118 quence of hMLH1 promoter hypermethylation in mycosis fungoides patients and may prevent transcription

119 in 21/35 (60%) SS patients and in 3/8 (38%) mycosis fungoides patients, all of whom had clonal blood

120 Sezary syndrome and 5 with rapidly enlarging mycosis fungoides plaques or tumors.

121 Fifty-one mycosis fungoides samples were analyzed for microsatelli

122 Eighteen cases of early mycosis fungoides were compared with 18 cases of eczemat

123 that only 60% of the deaths attributable to mycosis fungoides were so certified.

124 In total, 260 patients with stage IA to IIA mycosis fungoides who had not used topical mechlorethami

125 Seven patients (44%) had cutaneous (all mycosis fungoides); 4 (25%) had peripheral T cell not ot

126 ease that recapitulates many key features of mycosis fungoides, a common variant of cutaneous T-cell

127 ung, and unknown primary tumors, meningioma, mycosis fungoides, and myeloid leukemia.

128 lar lymphoma, diffuse large B-cell lymphoma, mycosis fungoides, and peripheral T-cell lymphoma, respe

129 goid, transient acantholytic dermatosis, and mycosis fungoides, and should be considered in elderly p

130 mas, with particular emphasis on tumor stage mycosis fungoides, as it is in these cases that p53 over

131 PTEN may be important in the pathogenesis of mycosis fungoides, but our data imply that this gene is

132 Thus, lesions clinically suspicious for mycosis fungoides, especially those that have failed chr

133 its total absence in PBLs from patients with mycosis fungoides, inflammatory cutaneous or hematologic

134 oma, n = 11; other B-cell lymphomas, n = 10; mycosis fungoides, n = 13; peripheral T-cell lymphoma, n

135 In the subset of patients with mycosis fungoides, P53 mutations were identified in six

136 Eligibility included mycosis fungoides, Sezary syndrome, or primary cutaneous

137 evels of TOX were significantly increased in mycosis fungoides, the most common type of cutaneous T-c

138 We also included tissue from two cases of mycosis fungoides, three normal skin biopsies, and three

139 erythroderma or Sezary syndrome and 11 with mycosis fungoides, were studied for the occurrence of st

140 oss on 1p and 9p were found in all stages of mycosis fungoides, whereas losses on 17p and 10q were li

141 MSI and disease progression in patients with mycosis fungoides, with 6 of 15 (40%) patients with MSI

142 from a Macaca nemestrina with CD8(+) T-cell mycosis fungoides-cutaneous T-cell lymphoma.

143 ype may contribute to disease progression in mycosis fungoides.

144 was associated with an older age of onset of mycosis fungoides.

145 ad chronic myelogenous leukemia, and one had mycosis fungoides.

146 tes the results to skin stage and outcome in mycosis fungoides.

147 10q and MSI in advanced cutaneous stages of mycosis fungoides.

148 specially in Sezary syndrome and transformed mycosis fungoides.

149 arge proportion of patients with early stage mycosis fungoides.

150 ssessment of peripheral blood involvement in mycosis fungoides.

151 feature of the large-cell transformation of mycosis fungoides.

152 usly as a single dose to eight patients with mycosis fungoides.

153 ll documented in a subgroup of patients with mycosis fungoides/Sezary syndrome (MF/SS).

154 BMC is not due to an intrinsic defect in the mycosis fungoides/Sezary syndrome patients' immune acces

155 ns and outcomes of a subset of patients with mycosis fungoides/Sezary syndrome who were treated with

156 d cases of cutaneous T cell lymphoma (CTCL) (mycosis fungoides/Sezary syndrome) undergo large cell tr

157 f 31 cutaneous T-cell lymphoma (CTCL) cases (mycosis fungoides/Sezary syndrome, SS) as well as in 5 o

158 e-agent lenalidomide in advanced, refractory mycosis fungoides/Sezary syndrome.

159 DLBCL: OR(allelic) = 1.12, P(trend) = 0.006; mycosis fungoides: OR(allelic) = 1.44, P(trend) = 0.015)

160 s antibody (1) had clinical efficacy against mycosis fungoides; (2) was well tolerated; (3) had a low

161 the second report of a transplant-associated mycosis in a heart transplant recipient, extend the prev

162 biological studies involving a case of fatal mycosis in a nonmyeloablative hematopoietic stem cell tr

163 list of fungi recognized as a cause of human mycosis in immunocompromised patients.

164 ndidiasis (OPEC) is a frequent opportunistic mycosis in immunocompromised patients.

165 sis (IA) is the most important opportunistic mycosis in immunosuppressed patients.

166 as emerged as the third most common invasive mycosis in order of importance after candidiasis and asp

167 nsidered the most prevalent endemic systemic mycosis in the Americas, but this situation might be cha

168 Recurrent epidemics of this mycosis in the southwestern United States have contribut

169 Patients with mycosis involving the sinuses, orbits, or central nervou

170 lastomycosis, a respiratory and disseminated mycosis of people and animals worldwide, expression of t

171 is revealed severe allergic bronchopulmonary mycosis pathology in H99-infected mice and evidence of p

172 The majority of therapeutic strategies for mycosis require the protracted administration of antifun

173 iosis marneffei is an emerging opportunistic mycosis seen in severely immunocompromised human immunod

174 ization for Research and Treatment of Cancer/Mycosis Study Group diagnostic criteria.

175 ation for Research and Treatment of Cancer / Mycosis Study Group.

176 lished model of an allergic bronchopulmonary mycosis that has also been used to test a number of immu

177 Chromoblastomycosis is a subcutaneous mycosis that remains a therapeutic challenge, with no st

178 diagnosed in 68 children (55.7%); among them mycosis was identified after radiological examinations i

179 evelop a broad antibody-like reagent against mycosis, wheat germ agglutinin (WGA) was linked to the e

180 s an emerging frequently fatal opportunistic mycosis whose immunopathogenesis is poorly understood.